# Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

> **NCT00704483** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 321 (actual)

## Conditions studied

- Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

## Interventions

- **DRUG:** SBR759
- **DRUG:** Sevelamer HCl
- **DRUG:** SBR759
- **DRUG:** Sevelamer HCl

## Key facts

- **NCT ID:** NCT00704483
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-08
- **Final completion:** —
- **Target enrollment:** 321 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00704483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00704483, "Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00704483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*